| Emmy Tian, | |
|
5460 E La Palma Ave, Anaheim, CA 92807-2023 | |
| (714) 463-7500 | |
| Not Available |
| Full Name | Emmy Tian |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 5460 E La Palma Ave, Anaheim, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730876467 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 35500 (California) | Primary |
| Provider Name | Marshall B Ketchum University |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1720101876 PECOS PAC ID: 9739075177 Enrollment ID: O20040224000463 |
News Archive
The new CBO projections find that the health law's expansion of health coverage will, from 2015–2024, cost $104 billion less than previously projected.
PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that the Company has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily topical eye drop formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) for the treatment of neovascular eye diseases.
At a meeting with analysts and investors today, members of the senior management team of NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, plan to unveil the company's strategic roadmap to drive continued growth and expand the market for its nCounter Analysis System and the related product portfolio.
Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.
Microscopic worms used for scientific research are living longer despite cellular defects, a discovery that is shedding light on how the human body ages and how doctors could one day limit or reverse genetic mutations that cause inherited diseases, according to a new University of Colorado at Boulder study.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emmy Tian, 8764 Steelhead Ct, Reno, NV 89523-8948 Ph: (775) 247-5382 | Emmy Tian, 5460 E La Palma Ave, Anaheim, CA 92807-2023 Ph: (714) 463-7500 |
News Archive
The new CBO projections find that the health law's expansion of health coverage will, from 2015–2024, cost $104 billion less than previously projected.
PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that the Company has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily topical eye drop formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) for the treatment of neovascular eye diseases.
At a meeting with analysts and investors today, members of the senior management team of NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, plan to unveil the company's strategic roadmap to drive continued growth and expand the market for its nCounter Analysis System and the related product portfolio.
Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.
Microscopic worms used for scientific research are living longer despite cellular defects, a discovery that is shedding light on how the human body ages and how doctors could one day limit or reverse genetic mutations that cause inherited diseases, according to a new University of Colorado at Boulder study.
› Verified 4 days ago
Tina Do Optometry, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 440 N Euclid St, Anaheim, CA 92801 Phone: 714-956-2785 | |
Dr. Derek Kwon Optometry, Inc Optometrist Medicare: Medicare Enrolled Practice Location: 731 N Euclid St, Anaheim, CA 92801 Phone: 714-533-8240 | |
Krupa J Patel, OD Optometrist Medicare: Medicare Enrolled Practice Location: 5460 E La Palma Ave, Anaheim, CA 92807 Phone: 714-463-7569 | |
Dr. Garrett Scott Wada, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 936 S Brookhurst St, Anaheim, CA 92804 Phone: 714-533-2525 Fax: 714-242-9564 | |
Ely R Almaleh, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Steven Hoffman, Optometrist Medicare: Medicare Enrolled Practice Location: 5460 E La Palma Ave, Anaheim, CA 92807 Phone: 714-463-7500 Fax: 714-992-7850 | |
Ms. Teresa Xuan Do, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 500 S Euclid St Ste D, Anaheim, CA 92802 Phone: 714-635-1100 Fax: 714-635-1155 |